AEFI data shows minuscule risk of bleeding, clotting after taking Covishield
There were no potential thromboembolic events reported following the administration of Covaxin.
By Newsmeter Network Published on 17 May 2021 12:12 PM GMT
Hyderabad: Bleeding and clotting cases following COVID-19 vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the National AEFI (Adverse Event Following Immunization) Committee to the ministry of health and family welfare said.
Alerts were raised in some countries on post-vaccination "embolic and thrombotic events" on 11 March 2021, particularly with AstraZeneca-Oxford vaccine (Covishield in India). A decision was taken to conduct an urgent in-depth analysis of the adverse events (AE) in India in the light of the global concerns.
The National AEFI Committee noted that as of 3 April 2021, 75,435,381 vaccine doses had been administered (Covishield 68,650,819; Covaxin 6,784,562). Of these, 65,944,106 were first doses and 9,491,275 second doses. Since the COVID-19 vaccination drive was initiated, more than 23,000 adverse events were reported through the Co-WIN platform from 684 of the 753 districts of the country. Of these, only 700 cases (9.3 cases per million doses administered) were reported to be serious and severe in nature.
The Committee has completed an in-depth case review of 498 serious and severe events, of which 26 cases have been reported to be potential thromboembolic (formation of a clot in a blood vessel that might also break loose and carried by the bloodstream to plug another vessel) events following the administration of Covishield vaccine with a reporting rate of 0.61 cases per million doses.
There were no potential thromboembolic events reported following the administration of Covaxin.
AEFI data showed that there is a very minuscule but definitive risk of thromboembolic events. The reporting rate of these events in India is around 0.61 per million doses, which is much lower than the 4 cases/million reported by UK's regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses.
It is important to know that thromboembolic events keep occurring in the general population as background and scientific literature suggests that this risk is almost 70 per cent less in persons of South and South East Asian descent in comparison to those from European descent.
MOHFW is separately issuing advisories to healthcare workers and vaccine beneficiaries to encourage people to be aware of suspected thromboembolic symptoms occurring within 20 days after receiving any COVID-19 vaccine (particularly Covishield) and report preferably to the health facility where vaccine was administered in case of symptoms like breathlessness; pain in the chest; pain in limbs/pain on pressing limbs or swelling in limbs (arm or calf); multiple, pinhead size red spots or bruising of skin in an area beyond the injection site; persistent abdominal pain with or without vomiting; seizures in the absence of previous history of seizures with or without vomiting; severe and persistent headache with or without vomiting (in the absence of previous history of migraine or chronic headache); weakness/paralysis of limbs or any particular side or part of the body (including face); persistent vomiting without any obvious reason; blurred vision or pain in eyes or having double vision; change in mental status or having confusion or depressed level of consciousness.
The government said that Covishield continues to have a definite positive benefit-risk profile with tremendous potential to prevent infections and reduce deaths due to COVID-19 across the world and in India. Over 13.4 crore doses of Covishield vaccine have been administered as on 27 April 2021 in India. MoHFW is continuously monitoring the safety of all COVID-19 vaccines and is promoting reporting of suspected adverse events, it said.
